GlassScriptPhysician profile
Douglas D Alorgbey
NPI 1871938647
$2,501.18
in general payments reported to CMS, 2019-2025
24 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $44.83 · 2021: $242 · 2022: $625 · 2023: $336 · 2024: $769 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.23 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $710.39 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $377.82 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $245.77 | 2024-2025 | |
| Angiodynamics, INC. | $129.27 | 2025 | Auryon Laser System 100-120 Vac |
| Mylan Specialty L.P. | $125.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $108.63 | 2024 | Voquezna |
| Novo Nordisk INC | $94.73 | 2020-2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $93.54 | 2022-2023 | |
| Amgen INC. | $79.86 | 2022-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $71.20 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $57.78 | 2021-2022 | |
| Nalu Medical, INC. | $46.77 | 2024 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.91 | 2022-2023 | Xifaxan |
| Abbvie INC. | $44.26 | 2021-2023 | Linzess |
| Genentech USA, INC. | $43.87 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $38.61 | 2025 | Airsupra |
| Dexcom, INC. | $33.16 | 2021-2022 | |
| Amarin Pharma, INC. | $32.02 | 2022 | |
| Abiomed | $26.43 | 2024 | Impella |
| Xeris Pharmaceuticals, INC. | $24.24 | 2023 | Keveyis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.67 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.60 | 2023 | Gattex |
| E.R. Squibb & Sons, L.L.C. | $17.05 | 2020 | |
| Pfizer INC. | $13.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Alorgbey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.